These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31678702)

  • 1. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
    Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
    Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    Lièvre A; Ouine B; Canet J; Cartier A; Amar Y; Cacheux W; Mariani O; Guimbaud R; Selves J; Lecomte T; Guyetant S; Bieche I; Berger F; de Koning L
    Br J Cancer; 2017 Dec; 117(12):1819-1827. PubMed ID: 29024937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
    Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
    Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
    de Mello RA; Marques AM; Araújo A
    World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
    Martinelli E; Ciardiello D; Martini G; Troiani T; Cardone C; Vitiello PP; Normanno N; Rachiglio AM; Maiello E; Latiano T; De Vita F; Ciardiello F
    Ann Oncol; 2020 Jan; 31(1):30-40. PubMed ID: 31912793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
    Ciardiello F; Tejpar S; Papamichael D
    Target Oncol; 2009 Dec; 4(4):311-22. PubMed ID: 19915942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
    Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
    Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
    Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
    Mizukami T; Izawa N; Nakajima TE; Sunakawa Y
    Drugs; 2019 Apr; 79(6):633-645. PubMed ID: 30968289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.
    Bhattacharya S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103916. PubMed ID: 36717006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.